Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Noga, Stephen J.
127  Ergebnisse:
Personensuche X
?
1

In-class transition (iCT) of proteasome inhibitor-based the..:

Rifkin, Robert M. ; Girnius, Saulius K. ; Noga, Stephen J....
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
2

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO O..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger M....
HemaSphere.  7 (2023)  S3 - p. e149880d , 2023
Link: https://doi.org/10.1097/..
 
?
3

P-114 In-class transition (iCT) from parenteral bortezomib ..:

Girnius, Saulius ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S97-S98 , 2023
Link: https://doi.org/10.1016/..
 
?
4

In-Class Transition from Bortezomib-Based Therapy to IRd is..:

Rifkin, Robert M ; Costello, Caitlin L ; Birhiray, Ruemu E...
Future Oncology.  20 (2023)  3 - p. 131-143 , 2023
Link: https://doi.org/10.2217/..
 
?
5

POSTER: MM-465 In-Class Transition (iCT) from Parenteral Bo..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S221 , 2023
Link: https://doi.org/10.1016/..
 
?
6

MM-465 In-Class Transition (iCT) from Parenteral Bortezomib..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S501 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Poster: MM-233 Evaluation of the Comparative Effectiveness ..:

Kambhampati, Suman ; Rifkin, Robert ; Costello, Caitlin...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S179 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Poster: MM-253 Efficacy, Safety, and Quality of Life (QoL) ..:

Manda, Sudhir ; Yimer, Habte A. ; Birhiray, Ruemu E....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S179 , 2022
Link: https://doi.org/10.1016/..
 
?
9

MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patie..:

Manda, Sudhir ; Yimer, Habte A. ; Birhiray, Ruemu E....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S416-S417 , 2022
Link: https://doi.org/10.1016/..
 
?
10

P-204: In-class transition (iCT) from parenteral bortezomib..:

Yimer, Habte ; Birhiray, Ruemu ; Boccia, Ralph...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S147-S148 , 2022
Link: https://doi.org/10.1016/..
 
?
11

MM-233 Evaluation of the Comparative Effectiveness of In-Cl..:

Kambhampati, Suman ; Rifkin, Robert ; Costello, Caitlin...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S415 , 2022
Link: https://doi.org/10.1016/..
 
?
12

P-196: In-class transition (iCT) from bortezomib (V)-based ..:

Costello, Caitlin ; Birhiray, Ruemu ; Kambhampati, Suman...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S143 , 2022
Link: https://doi.org/10.1016/..
 
?
13

P-208: Ongoing trials investigating in-class transition (iC..:

Noga, Stephen ; Lee, Hans ; Whidden, Presley...
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S153 , 2021
Link: https://doi.org/10.1016/..
 
?
14

Feasibility of Long-term Proteasome Inhibition in Multiple ..:

Manda, Sudhir ; Yimer, Habte A. ; Noga, Stephen J....
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  11 - p. e910-e925 , 2020
Link: https://doi.org/10.1016/..
 
?
15

MM-202: Long-Term Proteasome Inhibition in Multiple Myeloma..:

Birhiray, Ruemu E. ; Manda, Sudhir ; Girnius, Saulius K....
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S299 , 2020
Link: https://doi.org/10.1016/..
 
1-15